Abstract
Background. Pamidronate is a second-generation bisphosphonate that has been used to attenuate post-renal transplant bone loss, but its effect on the function of the renal allograft is unclear. Therefore, we evaluated the long-term renal function in 57 subjects who had participated in a prospective, randomized clinical trial using pamidronate to attenuate bone loss in the renal transplant recipient. Methods. Thirty subjects (PAM) received intravenous pamidronate, 60 mg at baseline post-transplant and 30 mg in months 1, 2, 3 and 6 post-transplant, while 27 subjects (CON) did not receive pamidronate. We followed renal function, need for renal replacement therapy following transplant rejection, and mortality for 3 years following the start of the original study. Results. PAM did not have increased incidence of renal dysfunction or mortality compared with CON at any time point during the 3 years of follow-up. The incidence of proteinuria was also not different between the two groups. Conclusions. The prophylactic use of pamidronate in the above doses to attenuate bone loss in renal transplant recipients is not associated with higher incidence of renal dysfunction or mortality in a 3 year follow-up study. These findings may support the use of bisphosphonates in the treatment of early renal transplant-related bone loss.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 2870-2873 |
| Number of pages | 4 |
| Journal | Nephrology Dialysis Transplantation |
| Volume | 19 |
| Issue number | 11 |
| DOIs | |
| State | Published - Nov 2004 |
Fingerprint
Keywords
- Bisphosphonates
- Renal osteodystrophy
- Renal transplant
ASJC Scopus subject areas
- Nephrology
- Transplantation
Cite this
Pamidronate used to attenuate post-renal transplant bone loss is not associated with renal dysfunction. / Lee, Sally; Glicklich, Daniel; Coco, Maria.
In: Nephrology Dialysis Transplantation, Vol. 19, No. 11, 11.2004, p. 2870-2873.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Pamidronate used to attenuate post-renal transplant bone loss is not associated with renal dysfunction
AU - Lee, Sally
AU - Glicklich, Daniel
AU - Coco, Maria
PY - 2004/11
Y1 - 2004/11
N2 - Background. Pamidronate is a second-generation bisphosphonate that has been used to attenuate post-renal transplant bone loss, but its effect on the function of the renal allograft is unclear. Therefore, we evaluated the long-term renal function in 57 subjects who had participated in a prospective, randomized clinical trial using pamidronate to attenuate bone loss in the renal transplant recipient. Methods. Thirty subjects (PAM) received intravenous pamidronate, 60 mg at baseline post-transplant and 30 mg in months 1, 2, 3 and 6 post-transplant, while 27 subjects (CON) did not receive pamidronate. We followed renal function, need for renal replacement therapy following transplant rejection, and mortality for 3 years following the start of the original study. Results. PAM did not have increased incidence of renal dysfunction or mortality compared with CON at any time point during the 3 years of follow-up. The incidence of proteinuria was also not different between the two groups. Conclusions. The prophylactic use of pamidronate in the above doses to attenuate bone loss in renal transplant recipients is not associated with higher incidence of renal dysfunction or mortality in a 3 year follow-up study. These findings may support the use of bisphosphonates in the treatment of early renal transplant-related bone loss.
AB - Background. Pamidronate is a second-generation bisphosphonate that has been used to attenuate post-renal transplant bone loss, but its effect on the function of the renal allograft is unclear. Therefore, we evaluated the long-term renal function in 57 subjects who had participated in a prospective, randomized clinical trial using pamidronate to attenuate bone loss in the renal transplant recipient. Methods. Thirty subjects (PAM) received intravenous pamidronate, 60 mg at baseline post-transplant and 30 mg in months 1, 2, 3 and 6 post-transplant, while 27 subjects (CON) did not receive pamidronate. We followed renal function, need for renal replacement therapy following transplant rejection, and mortality for 3 years following the start of the original study. Results. PAM did not have increased incidence of renal dysfunction or mortality compared with CON at any time point during the 3 years of follow-up. The incidence of proteinuria was also not different between the two groups. Conclusions. The prophylactic use of pamidronate in the above doses to attenuate bone loss in renal transplant recipients is not associated with higher incidence of renal dysfunction or mortality in a 3 year follow-up study. These findings may support the use of bisphosphonates in the treatment of early renal transplant-related bone loss.
KW - Bisphosphonates
KW - Renal osteodystrophy
KW - Renal transplant
UR - http://www.scopus.com/inward/record.url?scp=8344249468&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=8344249468&partnerID=8YFLogxK
U2 - 10.1093/ndt/gfh504
DO - 10.1093/ndt/gfh504
M3 - Article
C2 - 15466880
AN - SCOPUS:8344249468
VL - 19
SP - 2870
EP - 2873
JO - Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
JF - Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
SN - 0931-0509
IS - 11
ER -